U.S. men's tennis star Ben Shelton is on the verge of a big win in the second round of Wimbledon on Thursday. While Shelton ...

John Stoltzfus, Oppenheimer chief investment strategist, joins CNBC's 'Squawk on the Street' to discuss how market could ...

Oppenheimer began coverage of Israel-based Camtek (NASDAQ:CAMT) with an Outperform rating and a $100 price target. Shares of ...

A Los Alamos home was featured in one of the biggest summer blockbusters. Now, a group is trying to open it up for the public ...

There are growing fears that immigration raids could hurt next year’s FIFA World Cup in Miami and 10 other U.S. cities ...

Filmmaker James Cameron calls "Oppenheimer" a "moral cop-out" for avoiding bombing aftermath scenes, as he develops his own ...

“Yeah…it’s interesting what he stayed away from,” Cameron, 70, told Deadline of Nolan, 54, when asked if he was surprised Oppenheimer won seven Oscars and grossed nearly $1 billion. “Look, I love the ...

James Cameron addressed Christopher Nolan's Oppenheimer, saying that the film was a 'moral cop out' due to a lack of certain ...

While the song’s backstory might be staged on its cover - a recreation of the moment Harry Houdini was supposedly passed a ...

This Best Picture Oscar winner sailed past $2 billion at the global box office, and it’s not Oppenheimer or Forrest Gump!

Filmmaker James Cameron has a critique of fellow director Christopher Nolan’s award-winning film, Oppenheimer.

Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year.